About this episode
Originally published on October 13, 2022, this episode features Luis in conversation with Dr. Paul Hergenrother from the University of Illinois. Dr. Hergenrother discusses Fabimycin, an antibiotic candidate targeting gram-negative bacteria. What is Fabimycin's mechanism of action? Which bacteria is it active against? Is there any intrinsic resistance? Tune in to find out!
Link to article: https://pubs.acs.org/doi/10.1021/acscentsci.2c00598
Questions? Feedback? Send those to [email protected]
Want to support the podcast? Here's how:
Venmo: https://venmo.com/u/letstalkmicro
Buy me a Ko-fi: https://ko-fi.com/letstalkmicro
Get every episode summarized
Each time Let's Talk Micro publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Let's Talk Micro
242: Microbiology & Infection Prevention: Partners in Crime
Let's Talk Micro
241: What Can Whole Genome Sequencing Realistically Tell Us About Resistance?
Let's Talk Micro
240: CLSI M100 2026: Actualizaciones
Let's Talk Micro
239: Inside ASM Microbe 2026
Let's Talk Micro